

MAR 1 9 2001

December 22, 2000

SUMMARY OF SAFETY AND EFFECTIVENESS

In accordance with the requirements of the Safe Medical Device Act of 1990 and 21 CFR 807.92, Linvatec Corporation is hereby submitting the 510(k) Summary of Safety and Effectiveness for the Super Revo® Suture Anchor 510(k) Number K003984

A. Submitter

Linvatec Corporation
11311 Concept Boulevard
Largo, Florida 33773-4908

B. Company Contact

Laura D. Seneff, RAC
Manager, Regulatory Affairs
(727) 399-5234 Telephone
(727) 399-5264 FAX

C. Device Name

Trade Name: Super Revo® Suture Anchor

Common Name: Suture Anchor

Classification Names: Fastener, Fixation, Nondegradable, Soft
Tissue, 21 CFR 888.3040

Proposed Class/Device: Class II

Product Code: MBI

Summary of Safety and Effectiveness

Device Name

510(k) # K603984

Date: December 22, 2000

Page 2 of 2

D. Predicate/Legally Marketed Devices

Revo® Preloaded Soft Tissue Anchor
Linvatec Corporation

Corkscrew
Arthrex, Inc.

E. Device Description

The Super Revo® is a titanium suture anchor with a self-tapping cutting tip. The anchor is preloaded with two sutures and is available either preloaded on a disposable driver or packaged separately.

F. Intended Use

The Super Revo® Suture Anchor is intended to be used for rotator cuff repairs in the shoulder either arthroscopically or in a mini-open technique.

G. Summary of Technological Characteristics:

The Super Revo® Suture Anchor is similar to the Linvatec Revo® Preloaded Suture Anchor and the Arthrex Corkscrew Suture Anchor. The technologies, design, materials and intended uses are similar for these devices.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

MAR 1 9 2001

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Laura D. Seneff, RAC
Manager, Regulatory Affairs
Linvatec
11311 Concept Boulevard
Largo, Florida 33773-4908

Re: K003984
Trade Name: Super Revo® Suture Anchor
Regulatory Class: II
Product Codes: MAI, HWC, GAS
Dated: December 22, 2000
Received: December 26, 2000

Dear Ms. Seneff:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97): Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten", with a long horizontal flourish extending to the right.

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and

Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

December 22, 2000

510(k) Number (if known): K603984

Device Name:

Indications for Use: The Super Revo® Suture Anchor is intended to be used for rotator cuff repairs in the shoulder either arthroscopically or in a mini-open technique.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒ OR Over-the-Counter Use ☐
(Per 21 CFR 801.109)

(Optional Format 1-2-96)

for Mark N. Milburn
(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

510(k) Number K003984